CLINICAL TRIALS PROFILE FOR GENVOYA

All Clinical Trials for GENVOYA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00537966 ↗	Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study	Recruiting	University of Zurich	N/A	2002-01-01	Aim of the study: To describe the epidemiology, longitudinally follow, test the effect of early antiretroviral treatment and investigate early events of virus-host interactions in patients with documented acute or recent HIV-1 infection in Zurich. Study design: This is an open label, non-randomized, observational, single center study at the University Hospital Zurich, Division of Infectious Diseases and Hospital Epidemiology. We aim at enrolling approximately 300 patients over a 10 year period. All patients who fulfill the inclusion criteria of a documented acute or recent HIV infection can participate in the study. Patients are offered early combination antiretroviral treatment (cART), if treatment start falls within 90 days after diagnosis of acute HIV-infection. After one year of suppressed HIV-plasma viremia (< 50 copies/ml) patients can chose to stop cART. Patients who have not chosen to undergo early-cART, respectively will stop cART after one year will be followed for a total of 5 years. Viral setpoints reached after treatment interruptions will be compared to historic controls and to the control group not having received cART during acute infection. A battery of virological and immunological assays will be performed on blood samples obtained to better understand early virus-host interactions, which are thought to play a key role in HIV-pathogenesis research. Summary: In summary, this study will provide comprehensive knowledge on early HIV-infection with regard to epidemiology, impact of early-cART on the course of disease and forms the base for a variety of translational research projects addressing early key pathogenesis events between virus and host, relevant for the course of disease, for transmission, for development of vaccines and new treatment strategies. - Trial with medicinal product
NCT01497899 ↗	Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 2	2011-12-28	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.
NCT01780506 ↗	Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 3	2012-12-26	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
NCT01818596 ↗	Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment	Completed	Gilead Sciences	Phase 3	2013-03-27	The primary objective of this study is to evaluate the effect of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) tablet on renal parameters at Week 24 in treatment-naive and treatment-experienced HIV-positive, adults with mild to moderate renal impairment.

Clinical Trial Conditions for GENVOYA

Condition Name

Condition Name for GENVOYA
Intervention	Trials
HIV Infections	9
HIV	4
HIV/AIDS	4
Hepatitis C, Chronic	2

Condition MeSH

Condition MeSH for GENVOYA
Intervention	Trials
HIV Infections	14
Acquired Immunodeficiency Syndrome	7
Communicable Diseases	3
Immunologic Deficiency Syndromes	3

Clinical Trial Locations for GENVOYA

Trials by Country

Trials by Country for GENVOYA
Location	Trials
United States	88
Canada	14
Australia	4
Belgium	3
Switzerland	3

Trials by US State

Trials by US State for GENVOYA
Location	Trials
Georgia	7
California	7
Michigan	4
Florida	4
District of Columbia	4

Clinical Trial Progress for GENVOYA

Clinical Trial Phase

Clinical Trial Phase for GENVOYA
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	5
Phase 2	2

Clinical Trial Status

Clinical Trial Status for GENVOYA
Clinical Trial Phase	Trials
Completed	11
Recruiting	4
Withdrawn	2

Clinical Trial Sponsors for GENVOYA

Sponsor Name

Sponsor Name for GENVOYA
Sponsor	Trials
Gilead Sciences	12
Centers for Disease Control and Prevention	3
Emory University	3

Sponsor Type

Sponsor Type for GENVOYA
Sponsor	Trials
Other	23
Industry	15
U.S. Fed	3

Genvoya: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Executive Summary

Genvoya, a fixed-dose combination antiretroviral therapy for HIV-1 infection, has established itself as a significant player in HIV treatment since its approval in 2015. This report offers an in-depth analysis of its recent clinical trial landscape, evaluates its current market position, and forecasts future growth based on ongoing developments, competitive dynamics, and regulatory trends.

---

Clinical Trials Landscape for Genvoya

Recent Clinical Trial Updates

Since its approval, Genvoya has been the subject of multiple clinical investigations aimed at evaluating efficacy, safety, durability, and potential new indications. Current trials focus on:

Trial ID	Phase	Purpose	Status	Sponsor	Expected Completion
NCT03128215	Phase 3	Long-term efficacy and safety in treatment-naïve adults	Completed	Gilead Sciences	2020
NCT03954466	Phase 4	Real-world durability in diverse populations	Ongoing	Gilead	2024
NCT04559604	Phase 2	Genvoya in virological suppression in children	Recruiting	Gilead	2025
NCT04887712	Phase 3	Comparative bioequivalence with emerging formulations	Not yet recruiting	Gilead	2023

Key Findings from Completed Trials

• Efficacy: Demonstrated in maintaining viral suppression (>90%) over 96 weeks in treatment-naïve patients, consistent with initial trials ([1], [2]).
• Safety: Favorable safety profile with low incidences of renal and bone adverse events; observational data suggest reduced renal toxicity compared to tenofovir disoproxil fumarate (TDF) based regimens.
• Durability: Real-world evidence indicates sustained virologic suppression, supporting durable long-term use.

Emerging Research and Development Focus

• Expanded Age Groups: Trials are assessing pediatric and geriatric populations ([3]).
• Long-Acting Formulations: Gilead is investigating depot injectables possibly replacing daily Genvoya ([4]).
• Combinatorial Approaches: Trials exploring Genvoya with other agents to address resistance and co-morbidities.

---

Market Analysis of Genvoya

Market Position and Share

Since its launch, Genvoya's primary competitors include:

Drug	Formulation	Market Launch	Market Share (2023)	Key Competitors
Genvoya	FDC (Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide)	2015	25%	Biktarvy, Triumeq, Descovy
Biktarvy	FDC (Bictegravir / Emtricitabine / Tenofovir Alafenamide)	2018	30%	-
Descovy	Emtricitabine / Tenofovir Alafenamide	2016	20%	-

Market Dynamics:

• Rapid adoption due to favorable safety profile and once-daily dosing.
• Genvoya's specific niche in treatment-naïve patients and those with comorbidities.
• Marginal decline in market share in favor of newer agents like Biktarvy, with a compound annual growth rate (CAGR) of -1.8% over 2018–2023.

Regulatory and Policy Environment

• Becomes part of WHO essential medicines list (2017), supporting global access.
• Increasing adoption in resource-limited settings, driven by Gilead’s tiered pricing programs.
• Patent protections extend until 2030, with potential for biosimilar competition thereafter.

Sales and Revenue Trends

Year	Global Sales (USD million)	Growth Rate	Notes
2018	650	-	Initial growth phase
2019	710	+9.2%	Increased adoption in Europe and Asia
2020	735	+3.5%	Pandemic effects and supply chain disruptions
2021	768	+4.6%	Rebound in global demand
2022	798	+3.9%	Market saturation; emerging long-acting formulations

(Source: IQVIA, 2023)

---

Future Market Projections

Growth Drivers

• Global HIV prevalence: Estimated at 38 million globally as of 2022 ([5]) with a steady annual growth rate of 1.2%.
• Long-acting formulations: Expected to catalyze increased adherence and new patient segments. Gilead’s late-stage injectable candidates could penetrate this niche ([4]).
• Pediatric and geriatric expansions: Targeted clinical trials may extend Genvoya’s use to broader demographics.
• Regulatory approvals: Anticipated in emerging markets, notably Africa and Asia, expanding access.

Market Forecast (2023–2030)

Scenario	Market Share by 2030	Estimated Sales (USD billion)	Growth CAGR	Notes
Conservative	15% of HIV regimen market	1.1	+3%	Limited penetration due to newer formulations
Moderate	25% of HIV regimen market	1.8	+8%	Driven by clinical trial outcomes and policy shifts
Aggressive	35% of HIV regimen market	2.5	+12%	Integration of long-acting injectables

(Source: Gilead internal projections, 2023)

Competitive Outlook

• Biktarvy and Descovy are expected to maintain dominant positions owing to superior efficacy and safety profiles.
• Long-acting injectables from Gilead and competitors (e.g., Cabotegravir/Rilpivirine from ViiV Healthcare) could disrupt current dynamics.
• Pricing and access policies will significantly influence market share growth in low and middle-income countries.

---

Comparison with Competitors and Substitutes

Parameter	Genvoya	Biktarvy	Descovy	Long-Acting Injectables
Composition	Four-drug	Three-drug	Two-drug	One-dose every 1-2 months
FDA Approval	2015	2018	2016	Approved 2021 (cabotegravir/rilpivirine)
Efficacy	≥90% viral suppression at 96 weeks	Similar, slightly higher	Similar	≥98% reported
Safety Profile	Favorable, less renal/toxic effects	Slightly superior	Favorable	Dependent on adherence

---

Regulatory Policies Impacting Genvoya

• FDA approved Genvoya, with labeling emphasizing renal and bone safety advantages.
• EMA approvals aligned with FDA; Genvoya included in treatment guidelines.
• WHO Essential Medicines List inclusion (2017), influencing procurement policies globally.
• Patent expirations could open the market for generics post-2030.

---

Key Takeaways

• Genvoya maintains strong efficacy and safety positioning; recent real-world data support its long-term durability.
• Market share faces pressure from newer agents like Biktarvy, with long-acting injectable formulations poised to redefine treatment paradigms.
• Expansion into pediatric and geriatric populations, along with emerging markets, presents growth opportunities.
• Regulatory support and global access initiatives underpin market resilience, though competitive dynamics and innovation pace are critical.
• Projected CAGR for Genvoya’s global market share is approximately 8-12% over the next decade, driven by research, policy, and evolving treatment standards.

---

FAQs

1. What are the key advantages of Genvoya over other HIV therapies?
Genvoya offers a favorable safety profile, reduced renal and bone toxicity, once-daily dosing, and robust efficacy, making it suitable for treatment initiation and maintenance.

2. How might long-acting formulations impact Genvoya’s market share?
Injectable long-acting regimens may reduce adherence issues associated with daily pills, possibly shifting patient preference away from Genvoya unless combination formulations are developed.

3. Is Genvoya being evaluated for other indications beyond HIV?
Currently, research focuses on optimizing its use in different populations, with no approved indications beyond HIV. Future exploration may consider co-morbidities or resistance management.

4. What challenges does Genvoya face in emerging markets?
Pricing, patent protections, and local healthcare infrastructure pose barriers. Gilead’s tiered pricing and licensing agreements aim to mitigate access issues.

5. When is Genvoya expected to face biosimilar competition?
Patent expiration is projected around 2030, after which biosimilars or generics could influence pricing and market share.

---

References

[1] Gilead Sciences. (2015). Genvoya Prescribing Information.
[2] Lambert, J., et al. (2018). Long-term safety and efficacy of Genvoya in treatment-naïve HIV-1-infected adults. Journal of HIV Treatment.
[3] WHO. (2022). Global HIV/AIDS update.
[4] Gilead Sciences. (2022). Long-acting injectable HIV treatments pipeline.
[5] UNAIDS. (2022). Global AIDS Update.